Feasibility and validity of using death surveillance data and SmartVA for fact and cause of death in clinical trials in rural China: a substudy of the China salt substitute and stroke study (SSaSS).
Liping HuangJie YuBruce NealYishu LiuXuejun YinZhixin HaoYangfeng WuLijing L YanJason Hy WuRohina JoshiJingpu ShiXiangxian FengJianxin ZhangYuhong ZhangRuijuan ZhangBo ZhouZhifang LiJixin SunYi ZhaoYan YuSallie-Anne PearsonZhengming ChenMaoyi TianPublished in: Journal of epidemiology and community health (2020)
Using mortality surveillance data for fact of death in clinical trials need to account for under-reporting. A face-to-face visit to all participants at the completion of trials may be warranted. Neither mortality surveillance data nor SmartVA provided valid data source for endpoint events.